£8.7M
The health technology company has closed a £8.7m Series B investment backed by high-profile angel investors.
"Low-cost, non-invasive technology for monitoring blood to a high standard is a holy grail that has profound, life-enhancing impact – whether you are monitoring metabolic health to improve athletic performance, or working to reverse the trend towards diabetes. I’m delighted to be working on developing such transformative products based on Zedsen’s novel non-invasive technology and being part of Zedsen’s amazing team."
Joseph R Grano + 4 others